Introduction
Malignant peripheral nerve sheath tumor (MPNST) is an uncommon soft tissue sarcoma with high metastatic potential and poor prognosis (1) . Surgical resection is a curative treatment of choice for resectable MPNST, whereas no effective systemic therapy is currently available for unresectable or metastatic MPNST (2) . The application of novel antitumor agents and precise prognostication are essential to improve the survival of MPNST patients.
A genetic characteristic of MPNST is that approximately half of the cases develop from benign neurofibroma in neurofibromatosis type 1 (NF1) patients with NF1 gene deficiency (3) .
NF1 is a kind of tumor suppressor gene encoding neurofibromin, the dysfunction of which leads to multiple neurofibromas through Ras activation (4, 5) . Ras activation, in turn, triggers the activation of two downstream pathways: the mitogen-activated protein kinase (MAPK) pathway and the AKT/mammalian target of rapamycin (mTOR) pathway. The loss of neurofibromin activity is not sufficient for malignant transformation from neurofibroma to MPNST. This suggests that additional alterations in p14 ARF , p15 INK4b , p16 INK4a (6, 7), p53 (8) , CHFR (9), CDK4, FOXM1 (10), HGF (11) , and MET (12) are necessary for the malignant transformation. However, the details of the molecular mechanism underlying the development of MPNST are poorly understood in NF1-related as well as sporadic cases.
The AKT/mTOR and MAPK pathways play important roles in modulating cellular functions in response to extracellular signals such as growth factors and cytokines (13, 14) .
AKT is a serine/threonine kinase that is activated (phosphorylated) by phosphoinositide 3-kinase (PI3K) and that in turn activates (phosphorylates) the downstream molecules. mTOR is one of the downstream targets of AKT and is a key factor in the AKT/mTOR pathway.
mTOR activates p70S6 kinase (p70S6K), directly or indirectly activates S6 ribosomal protein (S6RP), and inhibits 4E binding protein 1 (4E-BP1). mTOR activation causes protein synthesis, which induces cell proliferation, survival, motility, invasion, and differentiation,
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Author Manuscript Published OnlineFirst on December 3, 2012; DOI: 10.1158/1078-0432.CCR- and finally it can lead to cancer initiation and progression (15) . The Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, also known as the MAPK pathway, also regulates a variety of cell functions including proliferation, growth, and survival (16). There is cross-talk between the AKT/mTOR and MAPK pathways; for example, Ras can activate the PI3K/AKT/mTOR pathway in addition to the Raf/MEK/ERK pathway; indeed, ERK can activate mTOR (17, 18) .
The AKT/mTOR and MAPK pathways are known to be activated in some kinds of sarcomas (19) (20) (21) (22) (23) , and several papers support that the AKT/mTOR and/or MAPK pathways, as well as their upstream receptor tyrosine kinases, are activated in MPNSTs (1, 24, 25) . At least in NF1 patients, it is conceivable that Ras activation caused by Nf1 gene deficiency may induce the subsequent activation of the AKT/mTOR and Raf/MEK/ERK pathways. These pathways may play important roles in the initiation and progression of MPNST. Nonetheless, the clinicopathologic and prognostic significance of the activation status of the AKT/mTOR and MAPK pathways has not been investigated well in either NF1-related or sporadic MPNSTs.
Here we performed a large-scale clinicopathologic and prognostic analysis of the AKT/mTOR and MAPK pathways in a series of 135 MPNST clinical specimens. We then tested the antitumor activity of the mTOR inhibitor (Everolimus) on MPNST cell lines in vitro.
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Materials and Methods

Patients and tumors
One hundred thirty-five paraffin-embedded MPNST specimens from 104 patients were Table 1 . The 91 primary cases included 46 males and 45 females whose ages ranged from 1 to 88 years (median 47 years). In all, 37 patients were diagnosed with NF1 based on the National Institutes of Health (NIH) criteria (28). Tumors were located in the extremities in 39 cases (thigh 18, upper arm 13, lower leg 6, forearm 2), in the trunk wall in 23 cases (back 9, buttock 7, chest wall 5, abdominal wall 2), in the spinal or paraspinal region in 11 cases, in the head and neck in 9 cases, in the retroperitoneum in 7 cases, and in the visceral organs in 2 cases. All primary tumors were treated surgically, accompanied by adjuvant chemotherapy or irradiation in 4 cases. The histologic tumor grade was assigned as either low-grade or high-grade (29) . As for staging of the primary tumors, the latest American Joint Committee on Cancer (AJCC) staging system was used (30) . Follow-up information was available in 88 out of the 91 primary tumor cases.
The median follow-up period after surgery was 26 months (range, 3-291 months).
This study was performed in accordance with the principles embodied in the Declaration of Helsinki. The study was also approved by the Ethics Committee of Kyushu University
Immunohistochemistry
Immunohistochemical staining was performed in the same way as described previously (19) . Sections were pretreated with Target showed cytoplasmic and/or nuclear staining with equal to stronger intensity compared to that of the endothelial cells, the expression was considered positive by reference to the previously published papers (22, 31) . The serial sections were also immunostained with anti-Ki-67 antibody (M 7240, 1:100; Dako, Glostrup, Denmark) using the standard procedure. The Ki-67-labeling index was calculated as described previously (32) .
Snap-frozen samples
Western blotting analysis
Western blotting (WB) analysis was performed as previously described (7, 37) using monoclonal antibodies of p-AKT (Ser473, 1:500 dilution), AKT (1:500), p-mTOR (Ser2448, 1:500), mTOR(1:500), p-S6RP (Ser235/236, 1:500), S6RP (1:1000), p-p70S6K (Thr389, 1:500), p-4E-BP1 (Thr37/46, 1:500), p-MEK1/2 (Ser221, 1:1000), p-ERK1/2 (Thr202/Tyr204, 1:500) and ERK1/2 (1:500). All the above antibodies were provided by Cell Signaling complete media containing the noted reagents and 30nM of Everolimus or carrier alone. The sizes of the scratches were imaged immediately (0 h) and at 6 h with a microscope (BZ-8000, Keyence, Osaka, Japan). Each assay was performed in triplicated and repeated four times.
Invasion assay
Invasion assays were performed with MPNST cell lines HS-Sch-2, HS-PSS, YST-1, FU-SFT8611, FU-SFT9817, and FMS-1 using the 24-well Biocoat Matrigel invasion chamber (BD Biosciences, Bedford, MA) according to the manufacturer's protocol. Briefly, cells were seeded into upper chamber at 1 × 10 5 per chamber in serum-free media. Outer wells were filled with media containing 5% FBS. The chambers were treated with 30nM of Everolimus or carrier alone. Cells were incubated at 37°C with 5% carbon dioxide for 22 h, and then non-invading cells were removed by wiping with a cotton swab. Cells that had migrated through the filter and adhered to its lower surface were fixed, stained using the Diff-Quik kit (Sysmex, Hyogo, Japan) as described previously (39) . The number of invading cells on membrane was counted in five microscopic fields (x400). Each assay was performed in triplicate and repeated three times. Data are expressed as the percentage of invasion through the Matrigel matrix and membrane relative to the migration through the control membrane according to the manufacturer's manual.
Statistical Analysis
Chi-square test or, when appropriate, Fisher's exact test was used to evaluate the association between 2 variables. Overall survival was adopted as the end point for survival
analyses. Survival curves were calculated with the Kaplan-Meier method, and the differences were compared by the log-rank test. Cox proportional-hazards regression analysis was
Results
Clinicopathologic variables and activation of the AKT/mTOR and MAPK pathways in MPNST specimens
MPNST cells showed cytoplasmic and/or nuclear staining for p-AKT, p-mTOR, p-S6RP, p-p70S6K, p-4E-BP1, p-MEK1/2, and p-ERK1/2 antibodies (Fig. 1) . In a case of MPNST arising from neurofibroma in a neurofibromatosis type 1 (NF1) patient, positivity for each factor in the AKT/mTOR pathway showed a clear contrast between MPNST and the benign neurofibroma area: positive staining in the MPNST area and, in contrast, negative staining in the neurofibroma area (Fig. S1 ). Table 1 Immunoreactivity for each antibody was confirmed by WB (Fig. S2) . The expression levels in WB corresponded closely to the levels in IHC. p-AKT, AKT, p-mTOR, mTOR, and p-p70S6K expressions were higher in tumor samples than in the corresponding normal tissue in both NF1-related and sporadic MPNSTs, while this tendency was not apparent for p-MEK1/2 and p-ERK1/2.
Prognostic significance of activation of AKT/mTOR and MAPK pathways in MPNST patients Among the factors of the AKT/mTOR and MAPK pathways we investigated, positivity for p-AKT (p=0.045), p-mTOR (p=0.0039), and p-S6RP (p=0.026) each showed a significant association with overall survival in univariate prognostic analysis (Table 2A , Fig. 2A-C) .
Combinatorial prognostic analysis with p-AKT and p-mTOR expressions showed that positive staining for both p-AKT and p-mTOR meant a worse prognosis than if either or neither of them was positive (Fig. 2D) . Furthermore, positive staining for more than two factors among p-AKT, p-mTOR, and p-S6RP indicated worse prognosis than the others (Fig. 2E) .
Meanwhile, the expressions of p-p70S6K and p-4E-BP1, which are downstream of the AKT/mTOR pathway, and expressions of p-MEK1/2 and p-ERK1/2, which are in the MAPK pathway, were not associated with overall survival (Table 2A, Fig. S3 ). Regarding NF1-related vs. sporadic MPNST, the former showed worse prognosis than the latter (p=0.029). Each of the following clinicopathologic variables was also associated with poor prognosis: tumor location in deep tissue, large tumor size (more than 5 cm), adjuvant therapy treatment, present tumor necrosis, high Ki-67 labeling index (more than 30%), epithelioid feature, high histologic grade, and advanced AJCC stage (stage II or higher).
A multivariate analysis was performed with each of p-AKT, p-mTOR, and p-S6RP and with clinicopathologic variables that were related to poor prognosis in the univariate analysis (Table 2B, S2) . Those 3 factors were excluded because AJCC stage was derived from them. The multivariate analysis revealed that each p-mTOR and p-S6RP positive expressions and high Ki-67 labeling index were the independent poor prognostic factors for overall survival (Table 2B ).
Antitumor effect of Everolimus for MPNST cell lines
Based on the clinicopathologic and prognostic analyses showing the importance of AKT/mTOR/S6RP pathway activation to the survival of MPNST patients, we chose Everolimus as an inhibitor for an in vitro experiment. Everolimus dose-dependently inhibited cell proliferation for all MPNST cell lines derived from both NF1-related and sporadic MPNSTs (Fig. 3A) . When compared with no drug controls, decreased p-S6RP and p-p70S6K expressions by Everolimus (30 nM, a dose achievable in humans by oral administration (40)) were confirmed by Western blotting (Fig. S4) and immunocytochemistry (Fig. S5) .
Everolimus administration showed no obvious effects on p-AKT, p-mTOR, p-MEK, and p-ERK1/2 expressions. A wound-healing assay showed a decrease in motility of all MPNST cell lines with Everolimus treatment (Fig. 3B) . In a Matrigel invasion assay, Everolimus caused a decrease in the invasion of all MPNST cell lines except for FU-SFT9817, which was one of the sporadic MPNST-derived cell lines (Fig. 3C ).
Discussion
We performed a large-scale and detailed clinicopathologic and prognostic assessment about AKT/mTOR and MAPK pathways in MPNSTs. To the best of our knowledge, our univariate prognostic analysis provided the first evidence that the activation of AKT, mTOR, and S6RP was associated with poor overall survival in MPNSTs. In addition, multivariate analysis identified p-mTOR and p-S6RP expressions as independent prognostic factors. These findings mean that, among AKT, mTOR, S6RP, p70S6K, 4E-BP1, MEK1/2, and ERK1/2, AKT/mTOR/S6RP activation is the most important process influencing prognosis in MPNSTs (Fig. 4) . Based on these findings, in terms of AKT/mTOR and MAPK signaling pathways, the inhibition of S6RP activation by mTOR inhibitor seems to be one of the most ideal treatment targets for clinically aggressive MPNST, in which systemic therapy is more likely to be needed. Everolimus is an orally bioavailable derivative of rapamycin and forms a complex with the FK binding protein complex (FKBP-12), which binds with high affinity to mTOR (40) . The Everolimus-mTOR interaction then causes the inactivation of p70S6K and S6RP. The advantage of Everolimus among AKT/mTOR/S6RP inhibitors is that it is already being used safely for cancer patients in clinical settings (40) . Our in vitro study showed that (24) . In addition, our study yielded the first evidence that mTOR inhibitor decreased cell motility and invasion on both NF1-related and sporadic MPNST cell lines, and also provided additional information on antiproliferation activity of Everolimus. In summary, mTOR inhibitors have been both characterized in the literature as leading to cell cycle arrest by suppressing cyclin D1 expression, inducing apoptosis, and inhibiting cell proliferation and angiogenesis, and shown to repress cell motility and invasion in our study. Recently, it was suggested that the mTOR inhibitor can induce paradoxical AKT activation due to a negative feedback loop between p70S6K and the insulin-like receptor substrate-1 (IRS1) (24, 43) and that it also can enhance MAPK pathway signaling (44) , which leads to resistance to the mTOR inhibitor. Our in vitro study showed no obvious gain in the expression levels of p-AKT, p-MEK1/2, and p-ERK1/2 after 30 nM of Everolimus was administered. Based on the findings of our in vitro study, it is reasonable to say that a single use of Everolimus is a potential novel drug therapy for sporadic and NF1-related MPNSTs. However, further in vivo and in vitro investigations in combination with other kinase inhibitors or cytotoxic agents are encouraged because the mTOR inhibitor might show stronger antitumor activity when administered in combination (24, 41, 45, 46) . This study revealed that AKT/mTOR/S6RP activation was not only suitable as a treatment target but also useful for prognostication. Combinatorial evaluation of p-AKT and p-mTOR expressions or p-AKT, p-mTOR, and p-S6RP expressions enables us to estimate the duration of patient survival precisely. It is easy to apply this prognosis prediction method to routine pathologic examinations, because it is based on immunohistochemistry of formalin-fixed, paraffin-embedded specimens. It is reasonable to conclude that p-AKT, p-mTOR, and p-S6RP expressions are useful prognostic indicators of MPNST, either individually or in combination. This is a large-scale clinicopathologic and prognostic study using whole tumor 
specimens. We employed whole tumor specimens instead of tissue microarrays because phosphorylated proteins in the AKT/mTOR and MAPK pathways sometimes show heterogeneous staining. The clinicopathologic analysis revealed that the AKT/mTOR and MAPK pathways were more frequently activated in deeply located MPNSTs than in superficial ones. A deeply situated tumor is often difficult to resect completely and is one of the factors in poor prognosis for MPNSTs. This finding implies that a deeply situated MPNST should be a good candidate for an AKT/mTOR inhibitor, because elevated p-AKT was associated with greater sensitivity for mTOR inhibitor in an endometrial cancer model (47).
4E-BP1 and ERK1/2 activation was associated with both high mitotic counts and high histologic grade. This is reasonable because 4E-BP1 and ERK1/2 are thought to regulate cell proliferation closely. Concerning a clinicopathologic study about portions of the AKT/mTOR and MAPK pathways, a few tissue microarray-based expression studies with a significant number of MPNST tumor samples have been reported (1, 24) . The authors of those studies reported 91% positivity for p-MEK1/2, which is very consistent with our result (93.4%). They had the same results as ours that p-MEK1/2 expression failed to show prognostic significance.
Also, their study showed that the AKT/mTOR pathway was less frequently activated than the MAPK pathway in MPNSTs; this was consistent with our result. They didn't make survival analysis with AKT/mTOR expression data; however, they found that higher p-AKT expression in metastatic lesions compared with localized cases (24) . Considering all the valuable data about the AKT/mTOR and MAPK pathways in clinical MPNST samples, in MPNSTs the MAPK pathway is more frequently activated than the AKT/mTOR pathway. 
